

Supplemental Table 5. Commonly Reported TEAEs ($\geq 5\%$ of Patients in Either Group or $\geq 3\%$ of Patients With a GI Disorder) Categorized by Other Race Patients

| System Organ Class (Preferred Term, MedDRA 19.1) | Lubiprostone 12 mcg BID (n=2), n (%) | Lubiprostone 24 mcg BID (n=1), n (%) | Total (N=3), N (%) |
|---|---|---|-----------------------------------|
| Patients with ≥ 1 TEAE | 1 (50.0) | 0 (0.0) | 1 (33.3) |
| Skin and subcutaneous tissue disorders | 1 (50.0) | 0 (0.0) | 1 (33.3) |
| Rash | 1 (50.0) | 0 (0.0) | 1 (33.3) |
| Contact dermatitis | 1 (50.0) | 0 (0.0) | 1 (33.3) |

BID = twice daily; GI = gastrointestinal; MedDRA = Medical Dictionary for Regulatory Activities; N = total population; n = subgroup of total population; TEAE = treatment-emergent adverse event.